His primary areas of investigation include Myeloid leukemia, Leukemia, Fms-Like Tyrosine Kinase 3, Cancer research and Quizartinib. His work deals with themes such as Lestaurtinib, Pharmacology and Tyrosine-kinase inhibitor, which intersect with Myeloid leukemia. The various areas that Mark J. Levis examines in his Lestaurtinib study include Sunitinib and Targeted therapy.
His Leukemia study integrates concerns from other disciplines, such as Chemotherapy, Myeloid and CD34, Stem cell, CD38. His research investigates the connection between Fms-Like Tyrosine Kinase 3 and topics such as Surgery that intersect with issues in Sorafenib, Cumulative incidence and Tolerability. His Cancer research study incorporates themes from Mutation, Tyrosine kinase, FLT3 Inhibitor and Receptor tyrosine kinase.
Mark J. Levis mainly focuses on Myeloid leukemia, Internal medicine, Cancer research, Leukemia and Oncology. His research in Myeloid leukemia intersects with topics in Quizartinib, Fms-Like Tyrosine Kinase 3 and Sorafenib. His Fms-Like Tyrosine Kinase 3 research integrates issues from Targeted therapy, FLT3 Inhibitor and FLT3 Internal Tandem Duplication.
His research integrates issues of Gastroenterology and Surgery in his study of Internal medicine. His studies in Cancer research integrate themes in fields like Mutation, Tyrosine kinase, Receptor tyrosine kinase and Tyrosine-kinase inhibitor. His studies examine the connections between Leukemia and genetics, as well as such issues in Pharmacology, with regards to In vivo.
His main research concerns Internal medicine, Myeloid leukemia, Oncology, Cancer research and Leukemia. As a part of the same scientific family, Mark J. Levis mostly works in the field of Internal medicine, focusing on Gastroenterology and, on occasion, Myeloproliferative neoplasm and Graft-versus-host disease. His Myeloid leukemia research incorporates themes from Quizartinib, Cancer, Incidence and Cohort.
His Oncology research includes themes of MRD Negative, Dasatinib, Sorafenib, Neutropenia and Allogeneic transplantation. His Cancer research study combines topics from a wide range of disciplines, such as Tyrosine kinase, FLT3 Inhibitor and Maintenance therapy. His studies in Leukemia integrate themes in fields like Myeloid, White blood cell, Fibrinogen and Hemoglobin.
His primary scientific interests are in Internal medicine, Myeloid leukemia, Oncology, Leukemia and Gastroenterology. His Midostaurin study, which is part of a larger body of work in Myeloid leukemia, is frequently linked to CYP3A, bridging the gap between disciplines. His Midostaurin study contributes to a more complete understanding of Cancer research.
He combines subjects such as Gilteritinib and Minimal residual disease with his study of Oncology. His research brings together the fields of Myeloid and Leukemia. The Gastroenterology study combines topics in areas such as Chemotherapy and Transplantation.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia
B. Douglas Smith;Mark Levis;Mark Levis;Miloslav Beran;Miloslav Beran;Francis Giles;Francis Giles.
FLT3: ITDoes matter in leukemia.
M Levis;D Small.
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
Patrick P. Zarrinkar;Ruwanthi N. Gunawardane;Merryl D. Cramer;Michael F. Gardner.
A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo
Mark Levis;Jeffrey Allebach;Kam-Fai Tse;Rui Zheng.
Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML
Zhihong Zeng;Yue Xi Shi;Ismael J. Samudio;Rui Yu Wang.
Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia
Farhad Ravandi;Jorge E. Cortes;Daniel Jones;Stefan Faderl.
Journal of Clinical Oncology (2010)
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
Mark Levis;Farhad Ravandi;Eunice S. Wang;Maria R. Baer.
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
Farhad Ravandi;Mona Lisa Alattar;Michael R. Grunwald;Michelle A. Rudek.
In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects
Mark Levis;Rosalyn Pham;B. Douglas Smith;Donald Small.
A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations
Mark Levis;Kam Fai Tse;B. Douglas Smith;Elizabeth Garrett.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: